End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
9.14 CNY | +2.24% | -.--% | -15.13% |
Apr. 25 | Jinyu Bio-technology Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
Feb. 27 | Taihe Technologies' Chief Financial Officer Resigns | MT |
Summary
- The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
Strengths
- Its core activity has a significant growth potential and sales are expected to surge, according to Standard & Poor's' forecast. Indeed, those may increase by 52% by 2025.
- The company's profit outlook over the next few years is a strong asset.
- The company's EBITDA/Sales ratio is relatively high and results in high margins before depreciation, amortization and taxes.
- The group's activity appears highly profitable thanks to its outperforming net margins.
- Thanks to a sound financial situation, the firm has significant leeway for investment.
- Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
Weaknesses
- The company's valuation in terms of earnings multiples is rather high. Indeed, the firm is getting paid 32.44 times its estimated earnings per share for the ongoing year.
- The company's "enterprise value to sales" ratio is among the highest in the world.
- The firm pays small or no dividend to shareholders. For that reason, it is not a yield company.
- For the last four months, the sales outlook for the coming years has been revised downwards. No recovery of the group's activities is yet foreseen.
- Over the past four months, analysts' average price target has been revised downwards significantly.
- The price targets of analysts who cover the stock differ significantly. This implies difficulties in evaluating the company and its business.
- The company's earnings releases usually do not meet expectations.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Pharmaceuticals
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-15.13% | 1.37B | B | ||
-9.60% | 6.64B | B- | ||
+24.75% | 3.7B | B- | ||
-2.09% | 3.12B | B- | ||
+3.89% | 1.45B | - | ||
-25.63% | 1.24B | C- | ||
-7.71% | 1.21B | - | ||
-10.84% | 1.17B | - | ||
-.--% | 1.05B | - | ||
-6.82% | 820M | D+ |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- 600201 Stock
- Ratings Jinyu Bio-technology Co., Ltd.